Cargando…
Interleukin-6 mediates resistance to PI3K-pathway–targeted therapy in lymphoma
BACKGROUND: The phosphoinositol 3-kinase (PI3K) pathway is associated with poor prognosis of hematologic malignancies, providing a strong rationale for the use of PI3K inhibitors in the treatment of malignant lymphoma. However, development of resistance limits the use of PI3K inhibitors in lymphoma...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785854/ https://www.ncbi.nlm.nih.gov/pubmed/31601188 http://dx.doi.org/10.1186/s12885-019-6057-7 |